|Bid||137.86 x 100|
|Ask||138.37 x 100|
|Day's Range||135.72 - 138.17|
|52 Week Range||96.93 - 138.17|
|PE Ratio (TTM)||51.72|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
When it comes to Celgene (CELG), what goes might must keep going up. Shares of Celgene started rallying on June 1, and after taking a break through the first couple of weeks of July, its shares are on the move again. In fact Celgene is trading a new 52-week high today.
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.